Trial Profile

A Phase Ib/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of JS015 Combination Therapy in Patients With Advanced Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 26 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Capecitabine (Primary) ; Fluorouracil (Primary) ; Folinic acid (Primary) ; Gemcitabine (Primary) ; Irinotecan (Primary) ; JS 015 (Primary) ; Oxaliplatin (Primary) ; Paclitaxel (Primary) ; Paclitaxel (Primary) ; Toripalimab (Primary)
Indications Adenocarcinoma; Colon cancer; Colorectal cancer; Gastric cancer; Oesophageal cancer; Pancreatic cancer; Pancreatic ductal carcinoma; Rectal cancer; Solid tumours; Squamous cell cancer
Focus Adverse reactions
Sponsors Shanghai Junshi Biosciences

17 Dec 2024 Planned End Date changed from 30 Apr 2026 to 28 Jan 2026.
17 Dec 2024 Planned primary completion date changed from 30 Nov 2025 to 1 Nov 2025.
17 Dec 2024 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com